First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.
about
First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
First-line use of rituximab co ...... spective, single-centre study.
@en
type
label
First-line use of rituximab co ...... spective, single-centre study.
@en
prefLabel
First-line use of rituximab co ...... spective, single-centre study.
@en
P2093
P2860
P50
P356
P1476
First-line use of rituximab co ...... ospective, single-centre study
@en
P2093
Carlos Panizo
Ignacio Herrero
Javier Pardo
José Rifón
Juana Merino
Pedro Errasti
Ramón Lecumberri
Ricardo García-Muñoz
Ángel Panizo
P2860
P356
10.1111/EJH.12782
P577
2016-06-28T00:00:00Z